Corporate Venture "Parents" Rarely Buy Or Partner With Biotech Investments
This article was originally published in Start Up
Executive Summary
Based on a five-year analysis of the biopharma investments of SR One, Novartis Venture Funds, and Johnson & Johnson Development Corp., the "parent" entities of these CVC arms rarely, if ever, forge partnerships with their biotech portfolios.